Interestingly, both RON loss or inhibition in the tumor cooperated with the T-cell checkpoint inhibitor CTLA-4 to reduce tumor growth with responses associated with increased intratumoral lymphocytes and higher T-cell activation markers. This evidence concerns the gene CTLA4 and neoplasm.